RecruitingNot ApplicableNCT06055504

Study of Personalized Allocation of Defibrillators in Non-ischemic Heart Failure (SPANISH-1)


Sponsor

Consorcio Centro de Investigación Biomédica en Red (CIBER)

Enrollment

900 participants

Start Date

Sep 6, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Prospective, randomised, multicentre, open-label study to assess the non-inferiority of a personalised precision strategy for Sudden Cardiac Death (SCD) prevention in patients with non-ischemic dilated cardiomyopathy with Left Ventricular Ejection Fraction (LVEF) ≤35%


Eligibility

Min Age: 18 Years

Inclusion Criteria6

  • Age ≥ 18 years at the time of screening.
  • Previously established diagnosis of Non-ischemic DCM
  • Optimised medical treatment at maximum tolerated doses for at least 3 months prior to the screening date.
  • NYHA functional class II-III.
  • LVEF ≤ 35% documented by CMR as study procedure.
  • Life expectancy greater than 12 months.

Exclusion Criteria7

  • History of coronary artery disease justifying the presence of ventricular dysfunction, defined as: history of coronary revascularisation or presence of significant coronary stenosis (≥50% in left main or ≥70% in a major epicardial artery) on invasive or non-invasive coronary angiography (coronary CT)
  • Left ventricular dysfunction attributed to congenital heart disease, valvular disease, alcohol abuse or chemotherapy.
  • Hypertrophic or infiltrative cardiomyopathy, active myocarditis or constrictive pericarditis.
  • History of recovered sudden death or sustained ventricular tachycardia.
  • NYHA functional class IV.
  • Waiting list for cardiac transplantation in emergency 0.
  • Receiver of a solid organ transplant (lung, liver, heart or kidney).

Interventions

OTHERControl Strategy

ICDs will be implanted in all patients according to current recommendations

OTHERPersonalized precision ICD implantation Strategy based in genetic findings and CMR results

Patients allocated to the intervention strategy will receive an ICD according to genetic and CMR results. ICD implantation criteria in patients allocated to the personalised strategy group will be the presence of either a DCM-causing pathogenic or likely pathogenic genetic variants or LGE in CMR. Patients without DCM-associated genetic variants and without LGE on CMR will not receive standard treatment but an ICD will not be implanted on them.


Locations(31)

H.C.U de Santiago de Compostela

Santiago de Compostela, A Coruña, Spain

H.U. de Bellvitge

L'Hospitalet de Llobregat, Barcelona, Spain

Hospital Parc Taulí

Sabadell, Barcelona, Spain

H.U. A Coruña

A Coruña, La Coruña, Spain

H.U. Puerta de Hierro

Majadahonda, Madrid, Spain

H.U. Central de Asturias

Oviedo, Principality of Asturias, Spain

Hospital General Universitario Dr Balmis

Alicante, Spain

H.U. de la Santa Creu i Sant Pau

Barcelona, Spain

H. Clinic de Barcelona

Barcelona, Spain

H.U. Germans Trias i Pujol

Barcelona, Spain

H.U. Vall d'Hebron

Barcelona, Spain

H.U. Josep Trueta

Girona, Spain

H.U. Virgen de las Nieves

Granada, Spain

Hospital Arnau de Vilanova

Lleida, Spain

H.G.U. Gregorio Marañón

Madrid, Spain

H.U. Ramón y Cajal

Madrid, Spain

H. Clínico San Carlos

Madrid, Spain

Hospital Universitario Fundación Jiménez Díaz

Madrid, Spain

H.U. 12 de Octubre

Madrid, Spain

H.U. Virgen de la Victoria

Málaga, Spain

H.C.U. Virgen de la Arrixaca

Murcia, Spain

H.U. Son Llátzer

Palma de Mallorca, Spain

Complejo Hospitalario de Navarra

Pamplona, Spain

H.U de Salamanca

Salamanca, Spain

H.U. Virgen del Rocio

Seville, Spain

Complejo Hospitalario Universitario de Toledo

Toledo, Spain

H.C.U de Valencia

Valencia, Spain

H.U. Politécnico de la Fe

Valencia, Spain

Hospital General Universitario de Valencia

Valencia, Spain

H.C.U de Valladolid

Valladolid, Spain

H.U. Miguel Servet

Zaragoza, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06055504


Related Trials